Junshi Biosciences (688180.SH): FDA approves clinical trial application for JS212 for late-stage solid tumors.

Zhtng Financial APP News, Junshi Biosciences (688180.SH) announced that the company has received notification from the US Food and Drug Administration ("FDA") that the clinical trial application for the EGFR/HER3 bispecific antibody conjugate drug (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA.